Stock Market News8 hours Keros Therapeutics Stock Plunges 81% in 3 Months: Here’s Why Zacks
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
XKROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
X